Innovent Biologics IPO Valuation: Surprisingly Grounded in Reality
Innovent Biologics Inc (1641475D HK) launched its Hong Kong IPO today. The mid-point of Innovent's IPO price range of HK$12.50-14.00 per share...
685 Views
Innovent Biologics IPO Preview: Limited Upside on China's PD-1 Drug Market Compared to BeiGene
Innovent Biologics Inc (1641475D HK) is the fourth pre-profit biotech firm to IPO in Hong Kong since Ascletis Pharma Inc (1672 HK), BeiGene Ltd...
686 Views
Last Week in GER Research: Haidilao, Popflops, Bitmain, Shandong Gold, Niu and China Renaissance
Below is a recap of the key IPO research produced by the Global Equity Research team. This week we highlight 25% potential downside at Haidilao as...
381 Views
Last Week in GER Research: Meituan, IPO Trading Strategy, Shandong Gold, Maoyan and Viomi
Below is a recap of the key IPO research produced by the Global Equity Research team. This week we highlight that Meituan is closer to fair value...
327 Views
Hua Medicine (华领医药) Post-Listing: Thin Volume and Limited Upside
Hua Medicine is the third biotech companies to list in Hong Kong without a profit under the amended listing rules. The stock debuted last Friday...
441 Views